” Global CAR T Cell Therapy Market & Clinical Trials Insight 2024″ Report Highlights:
- CAR T-Cell Therapies Delivery Pipeline & Mechanism of Action
- Sales Analysis of CAR – T Cell Therapy
- CAR – T Cell Therapy Market Opportunity: US$ 700 Million
- CAR-T Cell Therapies Clinical Pipeline by Company, Indication & Phase: 236 Therapies
- CAR-T Cell Therapies in Highest Phase: Preclinical
- Marketed CAR-T Cell Therapies: 2 ( Yescarta & Kymriah)
- Global Market Scenario of CAR T Cell Therapy
- Global CAR T Cell Therapy Market Future Prospects
Download Report: https://www.kuickresearch.com/report-global-car-t-cell-therapy-market-opportunity-and-clinical-pipeline-insight-2024.php
KuicK Research report on the ‘global CAR-T cell Therapy market’ is a result of intensive study of the novel segment and its future market potential. The report has been made with key focus on the current market trends, CAR-T cell products and their superiority to traditional cancer therapy methods. The report also provides key insights into the market performance of existing CAR-T cell products, recent developments and market dynamics that might impact its future. The report concludes with effective forecast data and future projections which clearly highlights it as one of the most promising market in the modern cancer therapy segment.
Table of Contents
- Chimeric Antigen Receptor (CAR) T Cell Therapy – Next Era in Immuno Oncology
1.1 Overview
1.2 History & Development of CAR-T Technology
- Development of Chimeric Antigen Receptor (CAR) T-Cell Design
2.1 Structure of CAR-T Cell
2.2 1st Generation Chimeric Antigen Receptor
2.3 2nd & 3nd Generation CAR-T Cell
- Chimeric Antigen Receptor Design Standards
3.1 CAR Modified T-Cells: Targeting
3.2 CAR Modified T-Cell: Signaling
- CAR T-Cell Therapies Delivery Pipeline & Mechanism of Action
4.1 Process of CAR T-Cell Therapy
4.2 Mechanism of Action
- Approaches to Improve the Efficacy of CAR-T Cell Therapy
5.1 Introduction
5.2 Targeting the Tumor Stroma with CAR-T Cells
5.3 Targeting the Cytokine Networks
5.4 Combination Strategies for CAR-T Cells
5.5 Targeting the Immune Checkpoints
- Global CAR T-Cell Therapy – Clinical Trials for Cancer Treatment
6.1 Acute Lymphoblastic Leukemia
6.2 Multiple Myeloma
6.3 Brain Tumors
6.4 Lymphoma
6.5 Solid Tumors
- CAR-T Cell Therapy Market Analysis by Product
7.1 Kymriah by Novartis
7.2 Yescarta by Gilead
- Recent Advances Impacting the CAR – T Cell Market
- Sales Analysis of CAR – T Cell Therapy
- Cost Analysis & Market Potential of CAR – T Cell Therapy
10.1 Manufacturing Cost Analysis of CAR-T Cell Therapy Products
10.2 Price Analysis of CAR-T Cell Therapy
10.3 Global – Estimated Potential Customer Base & Revenue Analysis
- Global CAR T-Cell Therapy Market Overview
11.1 Market Share of Cancer Immunotherapy by Technique
11.2 CAR-T Cell Therapy Market Value
- Global CAR-T Cell Therapy Market Dynamics
12.1 Favorable Parameters
12.2 Challenges
- Global CAR-T Cell Therapy Market Future Outlook
- Global CAR-T Cell Therapies Clinical Pipeline by Company, Indication & Phase
14.1 Research
14.2 Preclinical
14.3 Clinical
14.4 Phase-I
14.5 Phase-I/II
14.6 Phase-II
- Marketed CAR-T Cell Therapies Clinical Insight
15.1 Axicabtagene Ciloleucel (Yescarta)
15.2 Tisagenlecleucel (Kymriah)
- Competitive Landscape
16.1 Autolus
16.2 Bellicum
16.3 Bluebird
16.4 Celgene
16.5 Cellectis
16.6 Celyad
16.7 Eureka Therapeutics
16.8 Fortress Biotech
16.9 Immune Therapeutics
16.10 Juno Therapeutics
16.11 Kite Pharma
16.12 Novartis
16.13 Sorrento therapeutics
16.14 TILT Biotherapeutics
16.15 Ziopharm
Contact:
Neeraj Chawla
Research Head
neeraj@kuickresearch.com
+91-11-47067990